Wordt geladen...
Regulatory considerations in oncologic biosimilar drug development
Biosimilar monoclonal antibodies are being developed globally for patients with different types of solid tumors and hematologic malignancies. Applications for proposed biosimilar monoclonal antibodies are being submitted to the regulatory authorities around the world and may increase patient access...
Bewaard in:
| Gepubliceerd in: | MAbs |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Taylor & Francis
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622730/ https://ncbi.nlm.nih.gov/pubmed/25961747 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1040973 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|